Plaint against COVID-19 drug claim  07/01/2020 19:26:42 

An ophthalmologist has approached the Indian Council of Medical Research (ICMR) and Union Ministry of AYUSH against the claim by Patanjali Ayurved that the company has developed cure for COVID-19 through Coronil and Swasari medicines.

In a statement, the Patanjali had claimed that after the drugs were administered, symptomatic patients had become asymptomatic in three to 15 days. It also claimed that clinical studies were done in places such as New Delhi, Meerut, and Ahmedabad.

K.V. Babu, the ophthalmologist, said in a letter to the Director-General, ICMR, that details of the study could not be found in the public domain. Also, whatever were available gave the impression that the studies did not meet the scientific standards stipulated in the ICMR guidelines published in 2017.

Surprisingly, the results of the clinical trials were published on Twitter and announced through a press conference in New Delhi on June 23, the letter said. The first case for the trial, however, was enrolled only on May 29, according to the Clinical Trial Registry-India. The estimated duration of the trial was two months, the letter added.

In his mail to the AYUSH Ministry, Dr. Babu pointed out that the advertising of Ayush drugs was in violation of Section 7 of the Drugs and Magic Remedies Act 1954, and Sections 33(I) and 33(J) of the Drugs and Cosmetics Act, 1940, as clearly emphasised in a government communication dated June 2.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Dear reader,

We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.

Support Quality Journalism

Dear subscriber,

Thank you!

Your support for our journalism is invaluable. Its a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.

The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.

We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.

Suresh Nambath

« Go back